PDCD1 and neoplasm: Indeed, MSS Colon 26 syngeneic tumor models were non‐responsive to anti‐PD‐1 therapy, but the combination of DMR with anti‐PD‐1 therapy significantly enhanced the suppression of tumor progression compared to either DMR or anti‐PD‐1 therapy alone (Figure 6B–D).